RxDoctor Payments Data

David Wilson, MD

Cardiovascular Disease · Tampa, FLNPI 1063607174

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $167,680 of the $258,361 with a category attached, or 64.9%. Medtronic accounts for 87.1% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $100,393, 9.8 times the $10,270 reported in 2019. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$258,361in general payments, 2019–2025

Across 681 payments — averaging $379.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$225K
  • Philips North America LLC$10K
  • Abbott$9K
  • Acutus Medical, Inc.$7K
  • Boston Scientific$3K
  • Angiodynamics, Inc.$2K
  • plus $3K from 9 others
$162,823in research payments, 2019–2025

Across 112 payments — averaging $1453.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$125K
  • Biotronik Inc.$37K

What the payments were for

  • Consulting fees$19,0817%
  • Speaking & faculty fees$167,68065%
  • Travel & lodging$47,38418%
  • Food & beverage$24,1459%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,361 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Medicare billing

Part B allowed, 2024
$301,333
Medicare patients
481
Services billed
2,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$110,162
XareltoRivaroxaban50$49,295
EntrestoSacubitril/Valsartan37$29,093
CorlanorIvabradine Hcl25$25,032
Dofetilide58$17,113
Metoprolol Succinate115$1,591
Flecainide Acetate25$1,030
SotalolSotalol Hcl11$546
Diltiazem 24hr Er (Cd)Diltiazem Hcl26$479
Atorvastatin Calcium26$326
Amiodarone Hcl11$312
Metoprolol Tartrate49$253
Carvedilol38$246
Lisinopril20$154
Warfarin Sodium12$67

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Tampa

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →